STAT’s Post

Today's headline from Fierce Biotech was an article from James Waldron titled "Zenas, MBX and Bicara all head to Nasdaq in hot day for biotech IPOs." Nice to see the #IPO market opening for biotech and that public markets apetitite for biotech remains alive and well. https://lnkd.in/eDHwgq7x For the year, public investment in biotech is trending towards the third highest total on record. (Data on public investment to date from BioCentury Inc.) Center for Integration of Science and Industry at Bentley University

🔬 📈 Biotech investors and corporate development professionals We've just launched Gosset, the platform that provides insights about biotech assets. Try our demo here: https://lnkd.in/gK2mUiTm and comment on this post to get early access to the full version (or just to help us spread the word:)

"2024 has seen investors gravitate toward late-stage assets that already have the scalability problem solved with a clear path to profitability, according to a new report from Pitchbook. Hartenbach agreed, telling BioSpace that scalability has become a key part of early due diligence in any sort of dealmaking or financing conversations.   That means early-stage biotechs, if they want to stand out, would be wise to show not only what their technology is capable of, but how they can make it at scale."

Whether facing a pipeline setback, managing asset transactions, or replacing sunsetting product revenues, most companies will eventually need to adapt their pipeline strategies. Today, Ovid’s President and COO, Meg Alexander, is presenting at the 2024 Fierce Biotech Summit to share key learnings from Ovid and other companies that have successfully navigated the challenges of pivoting and rebuilding a company’s pipeline. Say hi if you are at the event: https://lnkd.in/gZiJ8nHE

AAX Biotech Secures Funding to Drive Technology Development and Expansion 🚀 We are excited to announce that AAX Biotech AB has successfully raised 7 MSEK in a funding round backed by both new and existing investors. The capital will be used to support our ongoing growth and innovation efforts, strengthening our internal capabilities and expanding our project portfolio. The funding round included a rights issue offered to current shareholders, alongside a directed share issue aimed at new investors such as Life Science Invest (LSI Epsilon). Several existing shareholders, including Karolinska Institutet Holding, Northislet, Hjalmar Didrikson through HJKK Didrikson AB and Phase2Phase Biopharma Ventures, additionally chose to increase their stake in AAX Biotech. With these resources, we are positioned to deliver innovative solutions that address some of the most critical medical challenges. Full story: https://lnkd.in/dcSBZ5Mm #AAX #Biotech #AntibodyTherapeutics #NextGenTherapeutics #DrugDevelopment

⏳ The countdown is on for Wilson Sonsini’s Inaugural Biotech Summit in Boston, October 9-10! ⌛ HIC's CEO and Principal Regulatory Advisor, Deb Autor, will share insights on FDA hot topics and regulatory trends alongside fellow industry leaders. Why attend? 👥 Connect with influential and knowledgeable leaders at the intersection of biotech, venture capital, and policy. ✍ Learn about regulatory trends, antitrust issues, and strategic collaborations that drive innovation in medical therapies. 🗣 Engage in topics that will highlight ways to leverage AI in healthcare. You don't want to miss this event! #BiotechSummit #FDA #Biotech #Boston #WilsonSonsini #Innovation #MedTech #PharmaBiotech #Regulatory

🌟 I'm thrilled to congratulate my friends, mentors, and former teammates at Formation Bio on a tremendously successful fundraise! 🌟 "Bring new treatments to patients faster and more efficiently" is an incredibly important mission. It also represents an incredibly long and difficult journey—one that I know Benjamine Liu would emphasize the team is just getting started on, despite how far we've already come! What does one fundraise mean for such a journey? It means well-deserved confidence in the team and its culture to realize the mission. It means realistic optimism for the vision of a world where every disease has a treatment. It means excitement in the potential for innovation at the intersection of AI, tech, and pharma. It means conviction to champion the mission. It's also a recognition of Ben's vision and unwavering resolve -- virtues that influenced me tremendously, as I know they have every Spark. I am immensely proud of this team, and excited to see more and more positive impact on the world through their journey. I'm beyond grateful for the portion of that journey I was able to make with them, and for the personal growth and learning imparted. Here's to the journey ahead, bringing new treatments to patients faster and more efficiently 🚀💡 #Innovation #Healthcare #Funding #AI #Tech #Pharma #ProudMoment

🌟 New Insights! 🌟 Don't miss Wilson Sonsini Goodrich & Rosati's latest Quarterly Life Sciences Report. This detailed analysis highlights the trends, key insights and developments in biotech and life sciences. LaunchBio's mission is to empower life sciences startups and foster an environment for innovation, and Wilson Sonsini's report is a great resource for anyone looking to stay informed about the current landscape and future directions in life sciences. Check it out below ⬇ #LifeSciences #Biotech #LaunchBio #WilsonSonsini #WSLifeSciReport

CDMO News - Scorpius BioManufacturing, Inc. Launches Scorpius Ventures to Support Biotech Onshoring with Hybrid Model. This initiative is designed to ease financial constraints for biotech firms by combining service fees with an equity stake in their operations. Learn more about it here at PharmaSource - https://lnkd.in/g-PaSrdW #CDMO #Biomanufacturing #Innovation PharmaSource Abby Sorensen Erika Morris